global dementia legacy event: dr. luc truyen, md, phd
DESCRIPTION
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia. Dr. Luc Truyen, MD, PhD, VP Neuroscience External Affairs and Chair, Johnson&Johnson, Global Fight against !lzheimer’s DiseaseTRANSCRIPT
![Page 1: Global Dementia Legacy Event: Dr. Luc Truyen, MD, PhD](https://reader035.vdocuments.site/reader035/viewer/2022070302/547d83eeb379593f2b8b52ce/html5/thumbnails/1.jpg)
Brian Jackson, Untitled 6Artwork from Reflections Art in Health
I have been impressed with the urgency of doing. Knowing is not enough; we must apply. Being willing is not enough; we must do. –Leonardo da Vinci
Luc Truyen MD PhDVP Neuroscience External Affairs Janssen and Chair, Global Fight against Alzheimer’s Disease, Johnson & Johnson
Program Director, Global Alzheimer’s Platform
Global Collaboration: key to conquering Alzheimer’s Disease
![Page 2: Global Dementia Legacy Event: Dr. Luc Truyen, MD, PhD](https://reader035.vdocuments.site/reader035/viewer/2022070302/547d83eeb379593f2b8b52ce/html5/thumbnails/2.jpg)
Disclaimer
The opinions expressed in this presentation are those of the presenter only and do not necessarily reflect the positions or opinions of Janssen Research and Development, L.L.C. or any other individual or affiliate of Johnson & Johnson. The presenter makes no warranties with respect to the accuracy of the data or materials presented herein. All information is provided for informational purposes only and does not constitute advice regarding clinical research-related activities.
![Page 3: Global Dementia Legacy Event: Dr. Luc Truyen, MD, PhD](https://reader035.vdocuments.site/reader035/viewer/2022070302/547d83eeb379593f2b8b52ce/html5/thumbnails/3.jpg)
Photograph by Judith Fox from I Still Do: Loving and Living with Alzheimer's
We need to change the dialogue:
From the 70 year old patient with Alzheimer’s Dementia
To the 40 year old person with Alzheimer’s Disease
![Page 4: Global Dementia Legacy Event: Dr. Luc Truyen, MD, PhD](https://reader035.vdocuments.site/reader035/viewer/2022070302/547d83eeb379593f2b8b52ce/html5/thumbnails/4.jpg)
Key needs to get to ‘disease interception’
Increased investment in basic science Incentivized innovators Identifying and capturing the right subjects for trials
– Clinimetrics– Diagnostics and Biomarkers– ‘Registries’
Translational infrastructure– Registries to trial ready cohorts– Sites that are qualified and ready with access to required tech– Effective trial designs: learn fast, confirm efficiently
Relevant outcomes– Surrogate markers– Sensitive cognitive measures– Economic impact models
A convergent, synchronized regulatory and payor environment
![Page 5: Global Dementia Legacy Event: Dr. Luc Truyen, MD, PhD](https://reader035.vdocuments.site/reader035/viewer/2022070302/547d83eeb379593f2b8b52ce/html5/thumbnails/5.jpg)
Global Alzheimer’s Platform
U.K.DementiaPlatform
AIBL
COLLABORATIONDATA SHARING KNOW HOW
AMP
WW-ADNI
We need a global
connectome
![Page 6: Global Dementia Legacy Event: Dr. Luc Truyen, MD, PhD](https://reader035.vdocuments.site/reader035/viewer/2022070302/547d83eeb379593f2b8b52ce/html5/thumbnails/6.jpg)
Thank you